JP2020537526A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537526A5 JP2020537526A5 JP2020521363A JP2020521363A JP2020537526A5 JP 2020537526 A5 JP2020537526 A5 JP 2020537526A5 JP 2020521363 A JP2020521363 A JP 2020521363A JP 2020521363 A JP2020521363 A JP 2020521363A JP 2020537526 A5 JP2020537526 A5 JP 2020537526A5
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus vector
- expression cassette
- vector according
- region
- adenovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000701161 unidentified adenovirus Species 0.000 claims description 40
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 8
- 241000282693 Cercopithecidae Species 0.000 claims description 5
- 108700019146 Transgenes Proteins 0.000 claims description 4
- 108020004705 Codon Proteins 0.000 claims description 2
- 230000000890 antigenic effect Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000001124 posttranscriptional effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 241001217856 Chimpanzee adenovirus Species 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572951P | 2017-10-16 | 2017-10-16 | |
| US62/572,951 | 2017-10-16 | ||
| PCT/EP2018/078212 WO2019076882A1 (en) | 2017-10-16 | 2018-10-16 | ADENOVIRAL VECTORS COMPRISING TWO EXPRESSION CASSETTES ENCODING RSV ANTIGENIC PROTEINS OR FRAGMENTS THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020537526A JP2020537526A (ja) | 2020-12-24 |
| JP2020537526A5 true JP2020537526A5 (enExample) | 2021-11-25 |
Family
ID=63896162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521363A Withdrawn JP2020537526A (ja) | 2017-10-16 | 2018-10-16 | Ｒｓｖ抗原性タンパク質又はその断片をコードする２つの発現カセットを有するアデノウイルスベクター |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11859199B2 (enExample) |
| EP (1) | EP3697919A1 (enExample) |
| JP (1) | JP2020537526A (enExample) |
| CN (1) | CN111527213A (enExample) |
| BR (1) | BR112020007008A2 (enExample) |
| CA (1) | CA3079048A1 (enExample) |
| MX (1) | MX2020003748A (enExample) |
| WO (1) | WO2019076882A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250066740A1 (en) * | 2020-07-06 | 2025-02-27 | Jiaxing Anyu Biotechnology Co., Ltd | Novel chimpanzee adenovirus vector, construction method therefor, and application thereof |
| WO2022102894A1 (ko) * | 2020-11-10 | 2022-05-19 | 주식회사 바이오리더스 | 코로나바이러스의 스파이크 단백질 및 뉴클레오캡시드 단백질을 동시발현하는 복제불능 아데노바이러스를 이용한 코로나바이러스 백신 |
| KR102399308B1 (ko) * | 2020-11-10 | 2022-05-20 | 주식회사 비엘 | 코로나바이러스의 스파이크 단백질 및 뉴클레오캡시드 단백질을 동시발현하는 복제불능 아데노바이러스를 이용한 코로나바이러스 백신 |
| KR102882279B1 (ko) * | 2022-05-09 | 2025-11-10 | 주식회사 모아라이프플러스 | 코로나바이러스의 스파이크 단백질, 뉴클레오캡시드 단백질 및 PgsA 단백질을 동시발현하는 복제불능 아데노바이러스를 이용한 코로나바이러스 백신 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005015728A1 (de) | 2005-04-06 | 2006-10-12 | Robert Bosch Gmbh | Verbindungsvorrichtung für einen Antrieb sowie Verfahren zur Herstellung einer Verbindungsvorrichtung |
| WO2008095027A2 (en) * | 2007-01-30 | 2008-08-07 | Cedars-Sinai Medical Center | Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene |
| CA2684578A1 (en) | 2007-03-21 | 2008-09-25 | Id Biomedical Corporation Of Quebec | Chimeric antigens |
| CA2749325C (en) | 2009-02-02 | 2021-03-30 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| WO2012021730A2 (en) * | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
| WO2012089231A1 (en) | 2010-12-30 | 2012-07-05 | Okairòs Ag | Paramyxovirus vaccines |
| US8865881B2 (en) | 2011-02-22 | 2014-10-21 | California Institute Of Technology | Delivery of proteins using adeno-associated virus (AAV) vectors |
| JP2016503422A (ja) | 2012-11-16 | 2016-02-04 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | プロスタグランジンｅｐ４アゴニストの組み合わせを用いた皮膚創傷の治癒および瘢痕の減少 |
| US11571472B2 (en) * | 2014-06-13 | 2023-02-07 | Glaxosmithkline Biologicals Sa | Immunogenic combinations |
| KR102535670B1 (ko) | 2015-06-12 | 2023-05-22 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 아데노바이러스 폴리뉴클레오티드 및 폴리펩티드 |
| GB201513176D0 (en) | 2015-07-27 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
-
2018
- 2018-10-16 CA CA3079048A patent/CA3079048A1/en not_active Abandoned
- 2018-10-16 MX MX2020003748A patent/MX2020003748A/es unknown
- 2018-10-16 JP JP2020521363A patent/JP2020537526A/ja not_active Withdrawn
- 2018-10-16 CN CN201880081339.5A patent/CN111527213A/zh not_active Withdrawn
- 2018-10-16 EP EP18789095.9A patent/EP3697919A1/en not_active Withdrawn
- 2018-10-16 BR BR112020007008-4A patent/BR112020007008A2/pt not_active IP Right Cessation
- 2018-10-16 WO PCT/EP2018/078212 patent/WO2019076882A1/en not_active Ceased
- 2018-10-16 US US16/756,380 patent/US11859199B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Das et al. | Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review | |
| Mezhenskaya et al. | M2e-based universal influenza vaccines: a historical overview and new approaches to development | |
| Dheerasekara et al. | Hantavirus infections—treatment and prevention | |
| JP2017515508A5 (enExample) | ||
| JP2008530245A5 (enExample) | ||
| JP2016513115A5 (enExample) | ||
| JP2020528911A5 (enExample) | ||
| JP2013506672A5 (enExample) | ||
| JP2017502662A5 (enExample) | ||
| JP2015533376A5 (enExample) | ||
| CA2764903C (en) | Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens | |
| WO2022135563A1 (zh) | 同时诱导抗多种病毒的免疫应答的方法 | |
| JP2021500880A5 (enExample) | ||
| US11859199B2 (en) | Adenoviral vectors with two expression cassettes encoding RSV antigenic proteins or fragments thereof | |
| ES3056141T3 (en) | Simian adenoviral vectors with two expression cassettes | |
| JP2012517239A5 (enExample) | ||
| JP4797149B2 (ja) | インフルエンザウイルスに対するベクターワクチン | |
| JP2025504364A (ja) | 慢性ｂ型肝炎感染症を処置または防止するための複数抗原治療ワクチン | |
| Kim et al. | Preparedness for Future Pandemics Using a Highly Effective Recombinant Vesicular Stomatitis Virus-Based Vaccine Platform Technology: Strategies for Developing Superior Vaccines. Medical Research Archives,[online] 13 (12) | |
| Lee et al. | Journal of Yeungnam Medical Science | |
| pertussis Novavax et al. | Covid-19 Vaccines: Several technologies at work | |
| JP2025506732A (ja) | 感染症およびがんの免疫療法適用のための多用途のウイルス様小胞（ｖｌｖ）プラットフォーム | |
| Tchilian et al. | Harnessing Local Immunity for an Effective Universal Swine In? uenza Vaccine. | |
| Sallberg et al. | 714. Attenuation of V-or C-Defective Measles Viruses: Infection Control by the Inflammatory and Interferon Responses of Rhesus Monkeys | |
| CN111328344A (zh) | 增强的启动子 |